Skip to main content

Table 1 Inflammatory breast cancer characteristics by race

From: Characterizing inflammatory breast cancer among Arab Americans in the California, Detroit and New Jersey Surveillance, Epidemiology and End Results (SEER) registries (1988–2008)

 

Arab

NHWa

NHBb

Hispanic

Asian

AI_Alc

p-value

(n=94)

(n=6,035)

(n=1,085)

(n=1,415)

(n=449)

(n=19)

n (%)

n(%)

n(%)

n(%)

n(%)

n(%)

Estrogen Receptor d

 

Positive

38 (42.2%)

2,219 (39.3%)

332 (32.1%)

491 (36.4%)

156 (36.7%)

7 (36.8%)

0.0070

 

Negative

36 (40.0%)

1,833 (32.4%)

391 (37.7%)

474 (35.1%)

156 (36.7%)

7 (36.8%)

 
 

Unknown

16 (17.8%)

1,598 (28.3)

313 (30.2%)

384 (28.5%)

113 (26.6%)

5 (26.3%)

 

Progesterone Receptor d

 

Positive

23 (25.6%)

1,762 (31.2%)

252 (24.3%)

380 (28.2%)

117 (27.5%)

4 (21.1%)

0.0003

 

Negative

50 (55.5%)

2,195 (38.8%)

453 (43.7%)

570 (42.2%)

189 (44.5%)

10 (52.6%)

 
 

Unknown

17 (18.9%)

1,693 (30%)

331 (32%)

399 (29.6%)

119 (28%)

5 (26.3%)

 

Combined Hormonal Status e

 

ER+ PR+

20 (27.4%)

1,597 (40.6%)

222 (31.6%)

336 (35.7%)

108 (35.3%)

4 (28.6%)

0.0002

 

ER+ PR-

17 (23.3%)

538 (13.7%)

98 (14%)

136 (14.4%)

44 (14.4%)

3 (21.4%)

0.0948

 

ER- PR+

3 (4.1%)

158 (4.0%)

28 (4%)

42 (4.5%)

9 (2.9%)

0 (0%)

0.8900

 

ER- PR -

33 (45.2%)

1,642 (41.7%)

354 (50.4%)

428 (45.4%)

145 (47.4%)

7 (50.0%)

0.0129

Her-2 Receptor f

 

Positive

14 (29.2%)

594 (21.9%)

94 (17.9%)

248 (29.9%)

83 (31.1%)

2(18.2%)

<0.0001

 

Negative

12 (25.0%)

906 (33.4%)

166 (31.7%)

310 (37.3%)

91 (34.1%)

5 (45.5%)

 
 

Unknown

22 (45.8%)

1,209 (44.6%)

264 (50.4%)

272 (32.8%)

93 (34.8%)

4 (36.3%)

 

Education g

 

High

36 (38.3%)

2,233 (37.0%)

183 (16.9%)

198 (14.0%)

128 (28.5%)

3 (15.8%)

<0.0001

 

Middle

30 (31.9%)

2,021 (33.5%)

249 (23.0%)

262 (18.5%)

127 (28.3%)

8 (42.1%)

 
 

Low

28 (29.8%)

1,781 (29.5%)

653 (60.2%)

955 (67.5%)

194 (43.2%)

8 (42.1%)

 

Menopausal Status

 

Pre (<50 yr)

25 (26.6%)

1,565 (25.9%)

389 (35.9%)

648 (45.8%)

162 (36.1%)

8 (42.1%)

<0.0001

 

Post (≥50 yr)

69 (73.4%)

4,470 (74.1%)

696 (64.1%)

767 (54.2%)

287 (63.9%)

11 (57.9%)

 

%No Education g

 

18.6 (15)

17.7 (13)

29.4 (18)

35.2 (21)

23.7 (17)

28.8 (18)

<0.0001

Age at diagnosis

 

58.5 (11.7)

60.1 (14.6)

56.2 (14.5)

52.6 (14)

54.0 (12.5)

54.8 (12.7)

<0.0001

Survival (months)

 

50.5 (51.3)

47.6 (49.3)

33.2 (37.5)

43.1 (44.2)

49.7 (47.4)

24.8 (25.7)

<0.0001

  1. aNHW=Non-Hispanic White.
  2. bNHB = Non-Hispanic Black.
  3. cAI_Al = American Indian/Alaskan native.
  4. d Sample size for ER and PR for cases diagnosed 1990–2008 only (NHW=5650, NHB=1036, Hispanic=1349, Arab=90, Asian=425, AI_Al=19).
  5. e Combined hormonal status based only on non-missing data from 1990–2008 (sample size for NHW = 3935, NHB=702, Hispanic =942 , Arab=73, Asian=306, Al_AI=14).
  6. f Sample size for HER2 for cases diagnosed 1999–2008 (NHW=1209, NHB=524, Hispanic=830, Arab=48, Asian=267, Al_AI=11).
  7. g% No Education (25 years of age or older without a high school diploma) and Education (tertiles of distribution) based on census tract-level information.
  8. *ANOVA test for continuous variables, chi-sq for categorical (or Fisher's exact test for cell counts <5), log-rank test for Survival.